Egrifta (Tesamorelin) and Zolpidem Interaction

Why This Drug Pair Gets Flagged

Patients receiving tesamorelin for HIV-associated lipodystrophy often carry a significant medication burden. Sleep disturbance is common in people living with HIV, with prevalence estimates ranging from 30% to 100% depending on the cohort and diagnostic criteria used [1]. Zolpidem is one of the most frequently prescribed sleep aids in the United States, with over 27 million dispensed prescriptions annually according to IQVIA data reported by the FDA. The probability that a patient on Egrifta will also receive zolpidem is not trivial.

Drug interaction databases typically flag this combination as a precautionary alert rather than a contraindication. The basis for the flag rests on pharmacodynamic reasoning, not on documented case reports of harm from the pair. Understanding exactly where the risk does and does not exist prevents unnecessary discontinuation of either medication.

Pharmacokinetic Assessment: Minimal Overlap

Tesamorelin is a 44-amino-acid peptide administered by subcutaneous injection. It does not undergo hepatic phase I or phase II metabolism in any clinically meaningful way. The Egrifta SV prescribing information states that tesamorelin is expected to be degraded by proteolytic enzymes into peptide fragments and amino acids, the same catabolic pathway that handles endogenous GRF [2]. No CYP induction, inhibition, or substrate competition has been identified for tesamorelin.

Zolpidem follows a different metabolic route. It is extensively metabolized in the liver, primarily by CYP3A4, with secondary contributions from CYP1A2, CYP2C9, and CYP2D6 [3]. The FDA-approved zolpidem label specifies that drugs inhibiting CYP3A4 (such as ketoconazole) can increase zolpidem exposure and that CYP3A4 inducers (such as rifampin) can reduce it. Because tesamorelin is a peptide that does not interact with CYP enzymes, it will not alter zolpidem plasma concentrations.

There is also no evidence that tesamorelin affects P-glycoprotein (P-gp) or other drug efflux transporters. Zolpidem is not a significant P-gp substrate. On the pharmacokinetic axis, this drug pair presents no actionable interaction.

Pharmacodynamic Concerns: Glucose and Sedation

The clinically relevant interaction between tesamorelin and zolpidem is pharmacodynamic, operating through two indirect pathways.

Growth hormone and glucose. Tesamorelin stimulates pulsatile GH release from the anterior pituitary. GH is a counter-regulatory hormone that opposes insulin action. The phase III trial program for Egrifta demonstrated that tesamorelin-treated patients experienced a modest increase in fasting glucose compared with placebo. In a 26-week randomized trial (N=816), mean fasting glucose increased by approximately 5 mg/dL in the tesamorelin group versus 1 mg/dL with placebo, and HbA1c rose by 0.12% versus 0.02% [4]. These changes were statistically significant but generally not clinically actionable in patients with normal baseline glucose. In patients with pre-existing impaired glucose tolerance or type 2 diabetes, the shift matters more.

Zolpidem and glucose. A population-based cohort study using Taiwan's National Health Insurance Research Database (N=59,312 zolpidem users matched to 177,936 controls) found that long-term zolpidem use was associated with a 41% increased risk of developing type 2 diabetes (adjusted HR 1.41, 95% CI 1.34 to 1.49) after controlling for comorbidities [5]. The mechanism is thought to involve disrupted sleep architecture and hypothalamic-pituitary-adrenal axis activation rather than a direct metabolic effect. A separate analysis published in Sleep Medicine confirmed that chronic Z-drug use correlated with higher HbA1c levels independent of sleep duration [6].

When both drugs are used together, the glucose-raising tendency of tesamorelin combines with the diabetes risk signal from chronic zolpidem use. This does not mean the combination is contraindicated. It does mean glucose monitoring should be deliberate.

Masking of hypoglycemia. In patients who are also taking insulin or sulfonylureas, zolpidem-induced sedation at bedtime could theoretically blunt awareness of nocturnal hypoglycemia. The counter-regulatory GH surge from tesamorelin typically acts to raise glucose, which may offer some protection, but the timing is unpredictable. Patients on complex metabolic regimens should be counseled to check blood glucose before taking zolpidem at bedtime.

Severity Rating Across Major DDI Databases

No single drug interaction database classifies the tesamorelin-zolpidem pair as "major" or "contraindicated." The interaction, where flagged, carries a mild-to-moderate severity rating based on the theoretical pharmacodynamic overlap described above. For context, the Lexicomp and Micromedex databases reserve their highest severity tier for combinations with documented serious adverse outcomes or strong mechanistic evidence of harm (e.g., QT prolongation with dual QT-prolonging drugs, or serotonin syndrome with dual serotonergic agents). The tesamorelin-zolpidem pair does not meet those thresholds.

The Egrifta SV prescribing information does list interactions with drugs that alter cortisol metabolism (since cortisol-binding globulin is a GH-sensitive protein) and notes the potential for altered insulin sensitivity, but it does not name zolpidem or Z-drugs as interacting agents [2].

Clinical Monitoring Protocol

Patients prescribed both tesamorelin and zolpidem should receive monitoring at these intervals:

Glucose parameters. Check fasting glucose and HbA1c before initiating tesamorelin, at 3 months, and every 6 months thereafter. This is the baseline recommendation from the Egrifta label regardless of concurrent medications [2]. If HbA1c rises above 6.5% or fasting glucose exceeds 126 mg/dL, reassess the benefit-risk ratio of continued tesamorelin therapy. The Endocrine Society clinical practice guideline on GH therapy in adults recommends the same glucose monitoring cadence for any patient receiving GH-axis stimulation [7].

Sedation and next-day impairment. The FDA issued a 2013 safety communication requiring lower recommended zolpidem doses, particularly for women (5 mg immediate-release, 6.25 mg extended-release), based on data showing that blood levels the morning after dosing were high enough to impair driving [3]. There is no evidence that tesamorelin potentiates zolpidem's CNS effects. GH-releasing peptides do not bind GABA receptors. The sedation monitoring here is standard zolpidem care, not interaction-specific.

IGF-1 levels. Tesamorelin raises IGF-1 by a mean of approximately 81% from baseline [4]. Elevated IGF-1 is an independent metabolic signal. While there is no evidence that zolpidem affects IGF-1, clinicians should track IGF-1 to ensure it remains below 3 times the upper limit of normal, per the Egrifta label's discontinuation criteria [2].

Dose Adjustment: None Required

Based on the absence of pharmacokinetic interaction and the low severity of the pharmacodynamic overlap, no dose adjustment of either tesamorelin or zolpidem is required when the two drugs are co-prescribed. Tesamorelin should remain at its standard dose of 2 mg subcutaneously once daily. Zolpidem dosing should follow the FDA's current recommendations: 5 mg (women) or 5 to 10 mg (men) for immediate-release formulations, taken only at bedtime with at least 7 to 8 hours remaining before planned awakening [3].

If a patient develops new-onset hyperglycemia while on both medications, the appropriate response is to manage the glucose disturbance through standard means (dietary modification, metformin initiation, or insulin adjustment) rather than empirically discontinuing either agent.

Patient Counseling Points

Patients receiving both medications should hear five specific messages:

1. Take zolpidem only at bedtime, immediately before getting into bed. Do not take it if you cannot stay in bed for at least 7 hours.
2. Do not consume alcohol on nights you take zolpidem. Alcohol compounds sedation and independently impairs glucose regulation.
3. If you use insulin or a sulfonylurea, check your blood glucose before taking zolpidem. Report any episodes of nighttime sweating, confusion on waking, or morning headaches to your prescriber.
4. Tesamorelin injections can be given at any time of day; the timing does not need to coordinate with or avoid your zolpidem dose.
5. Attend all scheduled lab draws. Your provider needs to track blood sugar and IGF-1 levels while you are on Egrifta.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment over any pharmacotherapy, including zolpidem [8]. Patients on tesamorelin who develop insomnia should be offered CBT-I before or alongside zolpidem to minimize long-term Z-drug exposure.

Other Tesamorelin Interactions Worth Knowing

While the zolpidem interaction is low-risk, tesamorelin does have interactions that warrant closer attention. The Egrifta prescribing information notes that tesamorelin-stimulated GH secretion can increase the conversion of cortisone to cortisol, which may unmask central adrenal insufficiency in patients with previously undiagnosed HPA axis deficiency [2]. Patients on exogenous glucocorticoids may need dose re-evaluation.

Tesamorelin also has the potential to reduce the efficacy of exogenous insulin and oral hypoglycemic agents through its GH-mediated counter-regulatory effects. A post hoc analysis of the tesamorelin phase III data found that diabetic patients on the drug required a mean increase of approximately 10% in their antihyperglycemic medication doses to maintain glycemic targets [9]. This is a more clinically impactful interaction than the zolpidem pairing.

Drugs that strongly suppress GH secretion (such as octreotide or high-dose glucocorticoids) could theoretically blunt the efficacy of tesamorelin, though this specific combination has not been studied in controlled trials.

The Bottom Line for Prescribers

The tesamorelin-zolpidem combination carries no pharmacokinetic interaction and a low-grade pharmacodynamic signal centered on glucose metabolism. Co-prescribing does not require dose modification, timing separation, or therapeutic substitution. It does require the same glucose monitoring that tesamorelin mandates for all patients: fasting glucose and HbA1c at baseline, 3 months, and every 6 months, with IGF-1 tracking to ensure levels remain below 3 times the upper limit of normal [2].